On July 10, 2014, the board of directors of Echo Therapeutics, Inc. appointed Charles T. Bernhardt to serve as Interim Chief Financial Officer of Echo, effective July 16, 2014. Mr. Bernhardt, age 53, is a Certified Public Accountant who most recently served as Chief Financial Officer and Chief Accounting Officer for publicly traded Hemispherx Biopharma, Inc. from 2009 through 2013, at which an excess of $60 million was raised during his tenure.
Echo Therapeutics, Inc.
Equities
ECTE
US27876L2060
Advanced Medical Equipment & Technology
1st Jan change | Capi. | |
---|---|---|
+7.87% | 223B | |
+11.83% | 195B | |
+18.87% | 144B | |
+30.03% | 111B | |
+2.32% | 65.19B | |
+14.15% | 53.02B | |
+2.68% | 50.28B | |
+6.60% | 44.15B | |
+1.85% | 36.45B |